![Daniel Tassé](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Daniel Tassé
Chief Executive Officer at
DBV TECHNOLOGIES
Net worth: 274 180 $ as of 31/08/2026
Profile
Mr. Daniel Tassé is a Chief Executive Officer & Director at DBV Technologies SA and a Lead Independent Non-Executive Director at REGENXBIO, Inc. He is on the Board of Directors at DBV Technologies SA, REGENXBIO, Inc., BioQ Pharma, Inc. and Roundtable On Critical Care Policy.
Mr. Tassé was previously employed as an Independent Director by HLS Therapeutics, Inc., a Chairman & Chief Executive Officer by Alcresta Therapeutics, Inc., a Senior Independent Director by Indivior PLC, a Member-Health Section Governing Board by Biotechnology Industry Organization, a Chairman, President & Chief Executive Officer by Ikaria, Inc., a GM-Pharmaceuticals & Technologies Business Unit by Baxter International, Inc., a Vice President & Regional Director-Australasia by GlaxoSmithKline Plc, a Member by Healthcare Leadership Council, and a Chief Financial Officer by NRG Energy Ltd. He also served on the board at Bellerophon Therapeutics, Inc. and Pharmaceutical Research & Manufacturers of America.
He received his undergraduate degree from the University of Montréal.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
REGENXBIO, INC. 0.04% | 29/05/2026 | 28,861 ( 0.04% ) | 274 180 $ | 31/08/2026 |
DBV TECHNOLOGIES SA -.--% | 15/04/2026 | 0 ( -.--% ) | - $ | 31/08/2026 |
Latest news about Daniel Tassé
Daniel Tassé active positions
| Companies | Position | Start |
|---|---|---|
| REGENXBIO INC. | Director/Board Member | 15/08/2016 |
| DBV TECHNOLOGIES | Chief Executive Officer | 29/11/2018 |
BioQ Pharma, Inc.
 BioQ Pharma, Inc. Medical SpecialtiesHealth Technology Designs and develops drug delivery systems for healthcare community | Director/Board Member | 01/12/2014 |
Roundtable On Critical Care Policy | Director/Board Member | - |
Former positions of Daniel Tassé
| Companies | Position | End |
|---|---|---|
Indivior Ltd.
 Indivior Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical drugs | Chairman | 19/11/2020 |
| BELLEROPHON THERAPEUTICS, INC. | Chief Executive Officer | 01/06/2014 |
| HLS THERAPEUTICS INC. | Director/Board Member | 01/03/2019 |
Alcresta Therapeutics, Inc.
 Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Develops enzyme-based products that deliver enzymatic solutions to those living with rare diseases | Chief Executive Officer | 01/11/2018 |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Director/Board Member | 01/06/2015 |
Training of Daniel Tassé
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
67
1st degree connections
16
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 16 |
|---|---|
Baxter International, Inc.
 Baxter International, Inc. Medical SpecialtiesHealth Technology Produces and supplies medical products, healthcare systems, therapies and pharmaceuticals & provide kidney care services | Health Technology |
BioQ Pharma, Inc.
BioQ Pharma, Inc. Medical SpecialtiesHealth Technology Designs and develops drug delivery systems for healthcare community | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Commercial Services |
Ikaria, Inc.
 Ikaria, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets therapeutics | Health Technology |
REGENXBIO, Inc.
 REGENXBIO, Inc. Pharmaceuticals: MajorHealth Technology Develops gene therapy | Health Technology |
Bellerophon Therapeutics, Inc.
 Bellerophon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engages in developing and commercializing of pharmaceutical products to treat cardiopulmonary diseases | Health Technology |
Indivior Ltd.
Indivior Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical drugs | Health Technology |
GSK Plc
 GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
University of Montréal
 University of Montréal Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
DBV Technologies SA
 DBV Technologies SA Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that focuses on changing the field of immunotherapy | Health Technology |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America BiotechnologyHealth Technology Provides pharmaceutical research and biotechnology services | Health Technology |
Healthcare Leadership Council
 Healthcare Leadership Council Medical/Nursing ServicesHealth Services Provides healthcare services | Health Services |
NRG Energy Ltd.
 NRG Energy Ltd. Food RetailRetail Trade Retails food products | Retail Trade |
Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Develops enzyme-based products that deliver enzymatic solutions to those living with rare diseases | Health Technology |
Roundtable On Critical Care Policy | |
HLS Therapeutics, Inc.
 HLS Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
- Stock Market
- Insiders
- Daniel Tassé
